Abstract: Heterocyclic dihydroxyquinoxaline compounds having the formula ##STR1## wherein R.sup.1 is halogen, CN, CF.sub.3, ethynyl, or N.sub.3 andR.sup.2 is SO.sub.2 C.sub.1-3 -alkyl, CF.sub.3, NO.sub.2, ethynyl, or CN.The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use.The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.

Abstract: A method for treating pain in human or non-human animals, which comprises administering an effective, non-toxic amount of paroxetine or a pharmaceutically acceptable salt thereof, to a sufferer.

Abstract: New heterocyclic compounds having the general formula ##STR1## wherein X is ##STR2## wherein R' is C.sub.1-6 -alkyl, C.sub.3-7 -cycloalkyl, phenyl, thienyl, or C.sub.1-3 -alkoxymethyl,R.sup.6 and R.sup.7 independently are hydrogen or halogen, and--A-- is --N(R")--C(O)--, --N(R")--CH.sub.2 --, or ##STR3## wherein R" is hydrogen, C.sub.3-7 -cycloalkyl, or C.sub.1-6 -alkyl The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

Abstract: New heterocyclic compounds having the general formula ##STR1## wherein X is ##STR2## or CO.sub.2 R' wherein R' is C.sub.1-6 -alkyl, C.sub.3-7 -cycloalkyl, or C.sub.3-7 -cycloalkymethyl,R.sup.6 and R.sup.7 independently are hydrogen, halogen, alkoxy, or trifluoromethyl, andR" hydrogen, C.sub.1-6 -alkyl, or C.sub.3-7 -cycloalkyl.The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

Abstract: New heterocyclic compounds having the general formula ##STR1## wherein X is ##STR2## wherein R.sup.1 is C.sub.1-6 -alkyl, Cphd 3-7-cycloalkyl, phenyl, thienyl, or C.sub.1-3 -alkoxymethyl,R.sup.6 and R.sup.7 independently are hydrogen or halogen, and--A--is --N(R")--C(O)--, --N(R")--CH.sub.2 --, or ##STR3## wherein R" is hydrogen, C.sub.3.differential. -cycloalkyl, or C.sub.1-6 -alkyl The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

Abstract: New oxadiazolyl imidazobenzodiazepine derivatives having the formula ##STR1## wherein R.sup.3 has the formula ##STR2## wherein R" is hydrogen, C.sub.1-6 alkyl C.sub.1-6 alkoxymethyl or C.sub.3-6 -cycloalkyl;R.sup.4 is hydrogen;R.sup.5 is C.sub.1-6 alkyl or R.sup.4 and R.sup.5 together form a 2-4 membered alkylene bridge; and R.sup.A is C.sub.1-6 alkyl, C.sub.1-6 alkoxy, or C.sub.1-3 trifluoroalkyl, pharmaceutical compositions thereof, and method of treating therewith, are disclosed.The compounds and pharmaceutical compositions are useful in the amelioration, mitigation, or elimination of central nervous system disorders related to benzodiazepine receptors and especially as anticonvulsants, anxiolytics, hypnotics, and nootropics.

Abstract: New benzodiazepine derivatives of the general formula ##STR1## wherein X.sup.1 and X.sup.2 independently are ##STR2## wherein R.sup.1 is C.sub.1-3 -alkyl, C.sub.3-5 -cycloalkyl, C.sub.1-3 -alkoxymethyl, C.sub.1-3 -hydroxyalkyl, or aryl,R.sup.4 is hydrogen, andR.sup.5 is C.sub.1-6 -alkyl, or wherein R.sup.4 and R.sup.5 together form a 2-4 membered alkylene chain.The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

Abstract: New heterocyclic compounds having the general formula ##STR1## wherein X is ##STR2## or CO.sub.2 R' whereinR' is C.sub.1-6 -alkyl, C.sub.3-7 -cycloalkyl, or C.sub.3-7 -cycloalkylmethyl,R.sup.6 and R.sup.7 independently are hydrogen, halogen, alkoxy, or trifluoromethyl, andR" is hydrogen, C.sub.1-6 -alkyl, or C.sub.3-7 -cycloalkyl.The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

Abstract: The application discloses novel benzodiazepine agonist compounds, namely, compounds having the formula ##STR1## wherein X is F, CF.sub.3, CH.sub.3, or CN, pharmaceutical compositions thereof, and a method of ameliorating central nervous system ailments therewith, especially convulsions and anxiolytic states. A novel intermediate and process for their production are also disclosed.

Abstract: A method for treating obesity in humans or non-human animals, which method comprises administering an effective, non-toxic amount of paroxetine or a pharmaceutically acceptable salt thereof, to obese humans or animals and compositions for use in such treatment.

Abstract: New oxadiazolyl imidazobenzodiazepine derivatives having the formula ##STR1## wherein R.sup.3 has the formula ##STR2## wherein R" is hydrogen, C.sub.1-6 alkyl C.sub.1-6 alkoxymethyl or C.sub.3-6 -cycloalkyl;R.sup.4 is hydrogen;R.sup.5 is C.sub.1-6 alkyl or R.sup.4 and R.sup.5 together form a 2-4 membered alkylene bridge; and R.sup.A is C.sub.1-6 alkyl, C.sub.1-6 alkoxy, or C.sub.1-3 trifluoroalkyl, pharmaceutical compositions thereof, and method of treating therewith, are disclosed.The compounds and pharmaceutical compositions are useful in the amelioration, mitigation, or elimination of central nervous system disorders related to benzodiazepine receptors and especially as anticonvulsants, anxiolytics, hypnotics, and nootropics.

Abstract: New oxadiazolyl imidazobenzodiazepine derivatives having the formula ##STR1## wherein R.sup.3 has the formula ##STR2## wherein R" is hydrogen, C.sub.1-6 alkyl C.sub.1-6 alkoxymethyl or C.sub.3-6 - cycloalkyl;R.sup.4 is hydrogen;R.sup.5 is C.sub.1-6 alkyl or R.sup.4 and R.sup.5 together form a 2-4 membered alkylene bridge; and R.sup.A is C.sub.1-6 alkyl, C.sub.1-6 alkoxy, or C.sub.1-3 trifluoroalkyl, pharmaceutical compositions thereof, and method of treating therewith, are disclosed.The compounds and pharmaceutical compositions are useful in the amelioration, mitigation, or elimination of central nervous system disorders related to benzodiazepine receptors and especially as anticonvulsants, anxiolytics, hypnotics, and nootropics.

Abstract: The compound (-)-trans-4-(4-florophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidin e and pharmaceutically-acceptable acid addition salts thereof, pharmaceutical compositions thereof, and their use in potentiating the 5-hydroxytryptamine(5-HT) of a subject in need thereof, for the alleviation of any of various physiological abnormalities, are disclosed.

Abstract: The compound (-)-trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine and pharmaceutically-acceptable acid addition salts thereof, pharmaceutical compositions thereof, and their use in potentiating the 5-hydroxytryptamine(5-HT) of a subject in need thereof, for the alleviation of any of various physiological abnormalities, are disclosed.

Abstract: A process for the optical resolution of the enantiomers of trans-3-[(4-methoxyphenoxy)-methyl]-1-methyl-4-phenylpiperidine, which involves reaction with an enantiomer of mandelic acid to form a mixture of diastereomeric compounds, precipitating one of the diastereoisomers, and converting it to the desirable free (+)-trans isomer, as well as the key diastereomeric isomer intermediate, is disclosed.

Abstract: New oxadiazolyl-imidazo-[1,4]benzodiazepine derivatives having benzodiazepine receptor activity have the formula ##STR1## R' is hydrogen, chlorine, fluorine or nitro in the 7- or 8-position, R.sup.1 is hydrogen or lower alkyl of up to 3 carbon atoms,R.sup.3 is the oxadiazolyl grouping of the formula ##STR2## wherein R" is lower alkyl with up to 3 carbon atoms and A B is a grouping of the formula ##STR3## wherein R.sup.5 is hydrogen or methyl and R'" is hydrogen or chlorine. The compounds possess valuable pharmacological properties. In particular, they act on the central nervous system and are suitable for use in psychopharmaceutical preparations.

Abstract: A method for assisting with appetite and weight control and reduction in obese human patients, which comprises the step of orally or rectally administering an appetite-suppressant compound selected from the group consisting of femoxetine and a pharmaceutically-acceptable salt thereof in an effective appetite-suppressant amount over a period of at least eight (8) weeks is disclosed. The appetite-suppresssant compound is preferably orally administered together with a pharmaceutically-acceptable carrier in a daily dosage of 100 to 1,000 mg in the form of a tablet containing about 100 to 300 mg of the appetite-suppressant compound, which is preferably a pharmaceutically-acceptable femoxetine acid addition salt, especially the hydrochloride.

Abstract: A .beta.-carbolin-3-carboxylic acid derivative of the formula ##STR1## has valuable pharmacological properties when administered to patients, e.g. humans as a drug, have been shown to possess interesting tranquilizing activity.

Abstract: The invention relates to new 3-substituted 1-alkyl-4-phenylpiperidines, being useful as antidepressant and anti-Parkinson agents, and to their production.